• Skip to main content
  • Skip to primary sidebar
  • Skip to footer
+49 (0) 69 / 606 278 – 0
[email protected]
Contact form
Patent- & Rechtsanwaltskanzlei

Patent- & Rechtsanwaltskanzlei

  • Deutsch

+49 (0) 69 / 606 278 – 0

  • Facebook
  • Twitter
  • Instagram
  • LinkedIn
  • xing
  • Email
MENUMENU
  • Services
    • Advice On Protective IP Rights
    • Patent Application /TM Registration
    • Enforcement Of IP Rights
    • Defence Against IP Rights Enforcement
    • Costs
  • Company
    • Fields of Law
      • Patent Law
      • Utility Model Law
      • Employees’ Inventions
      • Trademark Law
      • Design Law
      • Trademark and Product Piracy
      • Expert Opinions
    • Our Law Firm
      • Dr. Karl-Hermann Meyer-Dulheuer
      • Dr. Tim Meyer-Dulheuer
      • Dr. Klaus Zimmermann
      • Zhichao Ying
      • Clara Elinor Grünewald
    • Commitment
  • Contact
    • Where To Find Us
    • Write us!
    • Request call back
  • Blog

New cancer therapy: In DE “mixed prices” – “pay for performance” in USA

6. September 2018

In Europe, approval of the new promising cancer therapy CAR-T is expected. The possibilities are enormous, but so are the costs. In America, manufacturers have therefore offered pay for performance – but in Germany the mixed prices for medicines have just been confirmed in a much-noticed ruling by the highest social court.

This is because pharmaceutical pricing in Germany has so far been based on so-called mixed prices: a uniform price has been set for a new drug, of which only some patients have a higher benefit, while others have a lower or no additional benefit. This practice means that innovative drugs are also developed if they only have an effect on rarer diseases or particularly severe forms of disease.

Since 2011, the reimbursement of costs for pharmaceutical manufacturers has been dependent on the assessment of additional benefits. The medical benefit of the new drug compared to the predominant therapy is evaluated. This additional benefit is classified into six classes – and on the basis of the classification these mixed prices are negotiated between drug manufacturers and the German health insurance companies.

Judgment on reimbursement amounts for mixed drug prices

Cancer therapyThis led to legal proceedings. In June 2017, the Berlin-Brandenburg Regional Social Court ruled on two actions brought by the central association of statutory health insurance funds (Spitzenverband Bund der Krankenkassen, (GKV)) for the determination of the reimbursement amount for two drugs (Eperzan® and Zydelig®). The GKV central association considered the mixed price formed by the arbitration board according to § 130b Social Security Code (Sozialgesetzbuch (SGB)) to be illegal and so the Berlin-Brandenburg Regional Social Court also ruled. In principle, the Regional Court argued with a justification obligation for the mixed price calculation, which in the opinion of the Regional Court was not sufficiently fulfilled.

Furthermore, the Regional Court expressed considerable legal objections against the calculation of a mixed price. A mixed price would lead to price distortions, since uneconomical drug prices would have to be reimbursed by the GKV for the treatment of patients without additional benefit. For the treatment of patients with additional benefits, on the other hand, the reimbursement of medicines at low prices would consistently violate the rights of pharmaceutical companies.

This was contradicted by the Federal Social Court. The ruling of the Federal Social Court and also the ruling from the pending appeal of July 4, 2018 calmed the German uproar over the pricing of new drugs. The reimbursement amount specifically determined by the complained of arbitration board is not objectionable under audit law. A reimbursement amount is to be fixed appropriate to the benefit, without the law containing in all details specifications on the criteria according to which the additional benefit determined by the Joint Federal Committee (Gemeinsamer Bundesausschuss (GBA)) is to be assessed in monetary terms. 

Pay for performance

Pay for performance (P4P) is a strategic form of remuneration that is based on success. In P4P programs in healthcare, the reimbursement of medical services is linked to the success of treatment and the level of service represented by key figures. The aim is to use differentiated financial incentives to motivate doctors and health care providers to improve the quality and efficiency of the health system, clinical quality, access to existing therapies and thus patient satisfaction.

Source: Wissenschaftliches Institut der AOK

What does this mean for the new cancer therapy CAR-T in Germany?

For the time being, therefore, pricing in Germany will remain a mixed price; a “pay for performance” option would contradict this. However, CAR-T cancer therapy offers an extraordinary hope for a cure within a short treatment period, although with sometimes severe side effects in the therapy. The European Medicines Agency recommended the approval of CAR-T therapy in June due to the exceptional chances of recovery.

Hopes for a cure are enormous, but the costs are also high

However, the prices called for this therapy in the USA by the manufacturers Gilead and Novartis are well-known and exorbitant. Gilead charges $373,000 for “Yescarta” (a therapy for B-cell lymphomas) and Novartis $474,000 for “Kymriah” (a therapy for leukemia), the Frankfurter Allgemeine Zeitung reported on August 25 (Andreas Mihm: “Hope for cancer cure for 400,000 euros”). Birgit Fischer, Managing Director of the German Association of Research-based Pharmaceutical Companies, was also quoted in this article by the FAZ. Individualised reimbursement is not a universal system alternative, but could be an interesting supplement to the current price system of mixed prices, according to Ms Fischer.

However, it is unclear how such a model Pay for performance could be structured in the statutory health insurance system.

For the time being, the new CART-T therapy will be available according to a proven procedure, and this means strictly regulated: the therapy should be reserved for patients for whom other treatment attempts are unsuccessful. The therapy should also only be carried out in specialised centres in order to ensure that it is used according to the indication. Good documentation in patient registers should also enable monitoring of therapy success and also make the risk profile clearer.

Do you also need support in protecting your patents or in healthcare and pharmaceutical law?

Please take your chance and contact us. Our lawyers are experienced in trademark and patent law, national and international law.

 

 

 

Sources:

Bundessozialgericht Terminbericht Nr. 31/18

Picture:

qimono /pixabay.com / CCO License  

  • share  
  • share 
  • share 
  • tweet  
  • share 

Category iconHealthcare & Lifesciences Tag iconGilead,  Novartis,  Pay for performance,  cancer therapy,  Federal Social Court,  mixed prices,  medicines,  CAR-T,  statutory health insurance system,  German health insurance system,  Joint Federal Committee,  Social Security Code,  mixed drug prices,  FAZ,  healthcare,  Germany

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

More articles about: Healthcare & Lifesciences

All articles

Blog Menu

  • Design Law
  • Healthcare & Lifesciences
  • International Intellectual Property
  • Licenses
  • News from our law firm
  • Overall
  • Patent Law
  • Product- and Trademark piracy
  • Trademark Law
This form uses Google Recaptcha.

You must accept cookies from Google recaptcha to use this form.

More information can be found in our privacy policy.

load form

Recent Posts

  • Own trademark application fails – despite comparable trademarks: Equal treatment? 5. March 2021
  • Intel to pay 2.2 billion in damages – to VLSI / Fortress Investment 5. March 2021
  • BGH “FRAND II” – SEP Licensing as Distributor? 2. March 2021
  • Suspension of infringement proceedings 1. March 2021

Fields of Law

  • Patent Law
  • Utility Model Law
  • Employees’ Inventions
  • Trademark Law
  • Design Law
  • Trademark and Product Piracy
  • Expert Opinions
  • Costs

Das könnte Sie auch interessieren:

1. December 2020
BGH: Criteria for SPC on active ingredient combinations

BGH: Criteria for SPC on active ingredient combinations

9. November 2020
BioNTech: Success with the Corona vaccine

BioNTech: Success with the Corona vaccine

3. November 2020
BPatG: medicinal products must be identifiable

BPatG: medicinal products must be identifiable

4. August 2020
Biocidal composition for antibiotics: Clariant patent remains revoked

Biocidal composition for antibiotics: Clariant patent remains revoked

14. July 2020
ECJ and grant SPC for new therapeutic use

ECJ and grant SPC for new therapeutic use

18. May 2020
EU Biopatent: Enlarged Board of Appeal annuls fundamental decisions

EU Biopatent: Enlarged Board of Appeal annuls fundamental decisions

Footer

Contact

Franklinstr. 61-63
D-60486 Frankfurt am Main
Germany

+49 (0) 69 / 606 278 – 0
+49 (0) 69 / 606 278 – 199
[email protected]

Customer Reviews

Meyer-Dulheuer MD Legal Patentanwälte PartG mbB Patentrecht, Markenrecht, Eigentum hat 4,78 von 5 Sternen 23 Bewertungen auf ProvenExpert.com

Fields of Law

  • Patent Law
  • Utility Model Law
  • Employees’ Inventions
  • Trademark Law
  • Design Law
  • Trademark and Product Piracy
  • Expert Opinions
  • Costs

Law Firm

  • Request non-binding call back
  • Info secure emails
  • Company
  • Our Law Firm
  • ISO Certificate
  • Privacy Policy
  • Data handling for clients
  • Imprint

Follow Us

  • Facebook
  • Twitter
  • Google+
  • LinkedIn
  • xing
  • Email

Newsletter Signup

This form uses Google Recaptcha.

You must accept cookies from Google recaptcha to use this form.

More information can be found in our privacy policy.

load form

© Patent- & Rechtsanwaltskanzlei Meyer-Dulheuer MD Legal Patentanwälte PartG mbB

Kontaktformular

 

Rufen Sie uns an, schicken Sie uns eine Mail oder füllen Sie das Kontaktformular aus.

+49 (0) 69 / 606 278 – 0
[email protected]

This form uses Google Recaptcha.

You must accept cookies from Google recaptcha to use this form.

More information can be found in our privacy policy.

load form

Contact Form

 

Give us a call, send us an email or fill out the contact form.

+49 (0) 69 / 606 278 – 0
[email protected]

This form uses Google Recaptcha.

You must accept cookies from Google recaptcha to use this form.

More information can be found in our privacy policy.

load form